Merck

HIRING · 3 OPEN AI

About

Job Description
In this role, the chosen candidate will work with a team of scientists tasked with identifying, developing, and deploying data-rich technologies aimed at improving the manner in which process understanding is gathered. The tools that we develop are as diverse as the team developing them, and in this Senior Scientist role, the chosen candidate will leverage fundamental process modeling, machine learning, and other innovative data science approaches to enable our process researc...

Merck

About

Updates & Highlights

North Penn hires special counsel for Merck appeal

MilliporeSigma's CTO on AI retrosynthesis, the Merck KGaA–Siemens deal and the chemistry that runs the autonomous lab

Merck Expands TL1A Lead With Positive Tulisokibart Results In UC

Recent Openings

Senior Director, Real World Data Scientist (all genders)

2026 Future Talent Program - Natural Language Processing (NLP) and Generative AI Research Intern

Senior Scientist, Deep Learning Engineer within Data-Rich Experimentation (DRE)

All Jobs

Senior Director, Real World Data Scientist (all genders)

2026 Future Talent Program - Natural Language Processing (NLP) and Generative AI Research Intern

Senior Scientist, Deep Learning Engineer within Data-Rich Experimentation (DRE)

Culture & Mission

Benefits & Perks

Health Insurance

Remote Work

Learning Budget

Generous PTO

401(k) Match

Competitive Salary

Tech Stack

Core Values

Innovation

Collaboration

Excellence

Impact

Office Locations

Team

Are you on the team at Merck?

News & Press

North Penn hires special counsel for Merck appeal

MilliporeSigma's CTO on AI retrosynthesis, the Merck KGaA–Siemens deal and the chemistry that runs the autonomous lab

Merck Expands TL1A Lead With Positive Tulisokibart Results In UC

Merck Scores Key Phase 3 Win For Novel Ulcerative Colitis Therapy

AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?

Merck reports positive Phase 3 tulisokibart results

Merck Stock’s New Drugs Were Already Answering The Big Question

Merck & Co.'s tulisokibart scores pivotal TL1A victory in ulcerative colitis

Merck’s Oncology Engine Is Still Accelerating (NYSE:MRK)

Merck’s IBD drug from $10.8B Prometheus deal claims its first Phase 3 win

Merck’s anti-TL1A antibody from Prometheus buyout passes ph. 3 test in ulcerative colitis

AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?

Merck's bowel disease drug meets main goal in late-stage trial

AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?

Merck (MRK) Reports Promising Phase 3 Study Results for Tulisoki

Merck's bowel disease drug meets main goal in late-stage trial

Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends

Merck (MRK) Wins FDA Expansions, Posts HIV Data, And Ends Lung Cancer Trial

Merck’s Tulisokibart Met Primary and Key Secondary Endpoints in the Phase 3 ATLAS-UC Induction-only Study in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

FDA Expands Merck Pneumococcal Vaccine Indication to Include At-Risk Children and Adolescents